Insider Selling: BioLife Solutions (NASDAQ:BLFS) Director Sells 4,523 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) Director Amy Duross sold 4,523 shares of the stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $24.51, for a total value of $110,858.73. Following the sale, the director directly owned 25,687 shares in the company, valued at approximately $629,588.37. This trade represents a 14.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Amy Duross also recently made the following trade(s):

• On Friday, November 21st, Amy Duross sold 1,000 shares of BioLife Solutions stock. The shares were sold at an average price of $26.00, for a total value of $26,000.00.
• On Wednesday, November 19th, Amy Duross sold 477 shares of BioLife Solutions stock. The shares were sold at an average price of $24.50, for a total transaction of $11,686.50.

BioLife Solutions Stock Performance

Shares of BioLife Solutions stock traded up $2.33 on Friday, reaching $26.53. 540,117 shares of the stock were exchanged, compared to its average volume of 456,202. The firm has a market cap of $1.28 billion, a PE ratio of -221.06 and a beta of 1.97. The firm’s 50 day moving average is $26.36 and its 200-day moving average is $24.10. BioLife Solutions, Inc. has a one year low of $19.10 and a one year high of $29.62.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on BLFS. HC Wainwright reiterated a “buy” rating and set a $32.00 price objective (up from $30.00) on shares of BioLife Solutions in a research report on Friday, August 8th. Zacks Research raised shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $31.20.

Institutional Trading of BioLife Solutions

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Amalgamated Bank raised its holdings in BioLife Solutions by 3.5% during the 3rd quarter. Amalgamated Bank now owns 10,898 shares of the medical equipment provider’s stock worth $278,000 after purchasing an additional 366 shares during the last quarter. Ameritas Investment Partners Inc. raised its stake in BioLife Solutions by 12.8% during the second quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock worth $83,000 after buying an additional 441 shares during the last quarter. Louisiana State Employees Retirement System lifted its holdings in BioLife Solutions by 2.9% in the third quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the medical equipment provider’s stock valued at $454,000 after buying an additional 500 shares during the period. Isthmus Partners LLC boosted its position in BioLife Solutions by 0.4% during the second quarter. Isthmus Partners LLC now owns 132,125 shares of the medical equipment provider’s stock valued at $2,846,000 after acquiring an additional 509 shares during the last quarter. Finally, Sei Investments Co. grew its stake in BioLife Solutions by 0.5% during the first quarter. Sei Investments Co. now owns 117,999 shares of the medical equipment provider’s stock worth $2,695,000 after purchasing an additional 547 shares during the period. Institutional investors and hedge funds own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.